Inventor · disambiguated record
Matthew W. Martin
Also filed as: MARTIN MATTHEW · MARTIN MATTHEW W
75 granted patents·18 pending applications·677 citations·filing 2004–2023
99Inventor score
Files withFORMA THERAPEUTICS INC62AMGEN INC11VALO HEALTH INC10VALO EARLY DISCOVERY INC5UNIV INDIANA TRUSTEES2
Top patents by PatentIndex Score
93 records- 0199US10829461B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 10, 2020·15 cites·12 claims
- 0299US10829462B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 10, 2020·15 cites·17 claims
- 0399US10377726B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·22 cites·10 claims
- 0499US10112915B23-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Oct 30, 2018·41 cites·31 claims
- 0598US11279681B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Mar 22, 2022·6 cites·20 claims
- 0698US10822316B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 3, 2020·10 cites·15 claims
- 0798US10494354B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·17 cites·17 claims
- 0898US10494353B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·17 cites·12 claims
- 0998US10472337B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 12, 2019·17 cites·12 claims
- 1098US10428031B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 1, 2019·15 cites·20 claims
- 1198US10421731B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 24, 2019·15 cites·19 claims
- 1298US10421732B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 24, 2019·16 cites·13 claims
- 1398US10414738B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·16 cites·20 claims
- 1498US10239845B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Mar 26, 2019·25 cites·42 claims
- 1598US10214501B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Feb 26, 2019·20 cites·38 claims
- 1698US10214500B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Feb 26, 2019·20 cites·35 claims
- 1797US10988450B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Apr 27, 2021·6 cites·14 claims
- 1897US10513501B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 24, 2019·11 cites·20 claims
- 1997US10494352B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·12 cites·20 claims
- 2097US10494351B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·12 cites·20 claims
- 2197US10464910B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 5, 2019·12 cites·15 claims
- 2297US10464909B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 5, 2019·12 cites·17 claims
- 2397US10457652B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 29, 2019·12 cites·18 claims
- 2497US10450283B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 22, 2019·14 cites·16 claims
- 2597US10450284B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 22, 2019·14 cites·13 claims
- 2697US10442776B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 15, 2019·15 cites·18 claims
- 2797US10336722B2Tetrahydroquinoline compositions as BET bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Jul 2, 2019·22 cites·47 claims
- 2897US9422281B2Benzopiperazine compositions as BET bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2014·Granted Aug 23, 2016·25 cites·35 claims
- 2996US11299484B2Inhibiting fatty acid synthase (FASN)FORMA THERAPEUTICS INC·Filed 2020·Granted Apr 12, 2022·3 cites·22 claims
- 3096US11111229B2Tetrahydroquinoline compositions as BET bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2020·Granted Sep 7, 2021·4 cites·22 claims
- 3196US10377769B2Benzopiperazine compositions as BET bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·10 cites·28 claims
- 3296US9388161B2Tetrahydroquinoline compositions as BET bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2014·Granted Jul 12, 2016·34 cites·44 claims
- 3394US10611750B2Tetrahydroquinoline compositions as bet bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Apr 7, 2020·7 cites·38 claims
- 3494US10479772B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 19, 2019·6 cites·13 claims
- 3594US10472342B2Compounds and compositions for inhibition of FASNFORMA THERAPEUTICS INC·Filed 2019·Granted Nov 12, 2019·4 cites·25 claims
- 3694US7776869B2Heteroaryl-substituted alkyne compounds and method of useAMGEN INC·Filed 2005·Granted Aug 17, 2010·20 cites·15 claims
- 3793US9745253B2Alpha-cinnamide compounds and compositions as HDAC8 inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Aug 29, 2017·10 cites·53 claims
- 3893US7754717B2Bis-aryl amide compounds and methods of useAMGEN INC·Filed 2006·Granted Jul 13, 2010·29 cites·16 claims
- 3992US11891365B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2021·Granted Feb 6, 2024·1 cites·23 claims
- 4091US7435823B2Compounds and methods of useAMGEN INC·Filed 2005·Granted Oct 14, 2008·19 cites·23 claims
- 4190US11814386B2Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitorsFORMA THERAPEUTICS INC·Filed 2022·Granted Nov 14, 2023·1 cites·20 claims
- 4290US10457655B2Compounds and compositions for inhibition of FASNFORMA THERAPEUTICS INC·Filed 2017·Granted Oct 29, 2019·3 cites·46 claims
- 4390US10399951B2Compounds and compositions for inhibition of FASNFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 3, 2019·5 cites·27 claims
- 4489US11274084B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Mar 15, 2022·1 cites·18 claims
- 4589US10538496B2Methods using HDAC11 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Jan 21, 2020·3 cites·5 claims
- 4689US10508088B2Methods using HDAC11 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 17, 2019·3 cites·11 claims
- 4788US11247987B2Inhibiting ubiquitin specific peptidase 30FORMA THERAPEUTICS INC·Filed 2018·Granted Feb 15, 2022·3 cites·24 claims
- 4888US10266487B2Alpha-cinnamide compounds and compositions as HDAC8 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Apr 23, 2019·4 cites·16 claims
- 4987US11345672B2Methods using HDAC11 inhibitorsVALO HEALTH INC·Filed 2019·Granted May 31, 2022·2 cites·19 claims
- 5087US10703764B2Benzopiperazine compositions as BET bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Jul 7, 2020·2 cites·19 claims
Showing the top 50 of 93 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →